ACC/AHA guidelines 20–1
acetazolamide 96
acute HF 9–10, 12, 68–73, 110–13
acute ischemic hepatitis 63–4
advanced health directive 141–2
age see also elderly patients
HF incidence 11–12
for transplantation 131
air travel 89–91
aldosterone antagonists 95, 96, 104–6
amyloidosis, cardiac 37–8
angiotensin receptor neprilysin inhibitor (ARNI) 106–7
angiotensin-converting enzyme (ACE) inhibitors 62, 97–9, 112
angiotensin-receptor blockers (ARBs) 62, 97, 99–100, 112
anthracycline chemotherapy 13, 46
aortic valve regurgitation 28
aortic valve stenosis 27–8
apixaban 109
arrhythmias 73–7
arrhythmogenic RV cardiomyopathy (ARVC)/dysplasia 34, 35
arterial hypertension 14, 26–7
atherosclerotic lesions (plaques) 25
athlete’s heart 45
atrial fibrillation and flutter 44, 45
autonomic reflexes, disturbance 19
beta-blockers 61, 62, 100–4, 112–13
bisoprolol 101
blood tests, HF diagnosis 73–4
blood transfusion 56–8
bone-marrow-derived mononuclear cells (BMSCs) 144
bortezomib 38
bronchospasm 103–4
busulfan 46
calcium sensitizers 110
cancer therapy, cardiotoxicity 13, 46–9
candesartan 99
captopril 99–100
cardiac cirrhosis 63
cardiac contractility modulation 125
cardiac defibrillators (ICDs), implantable 115–17
cardiac magnetic resonance imaging (CMR) 75–6
cardiac resynchronization therapy (CRT) 117–25
cardiac surgery 126–33
cardiac transplantation 130–3
CardioMEMS™ HF system 124
restrictive 36–41
cardiorenal interactions 20
carmustine 46
central sleep apnea (CSA) 59–61, 87–8, 145–6
CHAMP 111
chronic obstructive pulmonary disease (COPD) 58–9, 103
cirrhotic cardiomyopathy 64
cisplatin 46
clinical markers, prognosis 135, 136
clinical stages in HF 20–1
clinical trials and developments 144–6
clozapine 42
coenzyme Q10 (CoQ10) 109
comorbidities 55–67, 80, 83, 93–5
congestive hepatopathy 63
continuous airway pressure (CPAP) 61
coronary artery disease (CAD) 25–6
coronary heart disease, HF risk 12–15
cosmic radiation 91
costs/benefits, CRT implants 120
CT scans 76
cyclophosphamide 46
dabigatran 109
deep vein thrombosis (DVT) 90
defibrillators, implantable 115–17, 119–20
in non-ischemic cardiomyopathies 116–17
definitions of HF 7–11
diagnosis of HF 68–77
diastolic HF 7–8
digoxin 108
parenteral 96–7, 111, 112, 145–6
doxorubicin 46
driving, HF and 89
drug trials
ACE inhibitors 98–9
aldosterone antagonists 105–6
ARBs 99–100
beta-blockers 100–4
drugs see also medication
cardiotoxicity 46–52
contraindicated 93, 98, 100, 101, 105, 110
dyspnea, management 140
echocardiography 28, 33, 42, 43, 74
CRT implant 123
edema, peripheral 30, 44, 97, 141
ejection fraction (EF) 7–9
elderly patients
coronary CT 76
CRT implants 122
HF management 79–80
electrocardiography 74
electromagnetic interference 90–1
enalapril 98
end-stage HF 137–42
endomyocardial fibrosis 41
epidemiology of HF 11–15
erectile dysfunction (ED) 87
erythropoiesis-stimulating agents (ESAs) 58
erythropoietin deficiency 56
exercise programs 83–5
extracorporeal membrane oxygenation (ECMO) 129
Fabry disease 38
factor Xa inhibitors 109
familial dilated cardiomyopathy (FDC) 35
fluid balance, monitoring 79–80, 95, 97
flying (travel) 89–91
folic acid deficiency 55–6
forced expiratory volume (FEV1) 58, 59
functional classes of HF 20–1
functional testing 76–7
Gheorgiades classification 73
glucose tolerance, impaired 45–6
glycogen storage diseases 34
heart failure with preserved ejection fraction (HFpEF) 7–9, 93, 102–3
heart failure with reduced ejection fraction (HFrEF) 9–10, 93–113
heart rate reduction 107–8
Heartmate, LV assist device 126–8
hemachromatosis 41
heparin 113
hepatitis, acute ischemic 63–4
hydralazine 109
hyperkalemia 145
hypertension, arterial 26–7
hypertrophic cardiomyopathy (HCM) 31–4
hypoxia, air travel 89–90
immunization, influenza 88
immunosuppressive regimen 132
implantable devices 79, 115–24 see also defibrillators; pacemakers
deactivation 142
interference 90–1
phrenic nerve stimulation 145–6
inflammatory cardiomyopathy 41–2
inotropic agents 109–10
insulin resistance 20
iphosfamide 46
iron, deposition 41
ischemic heart disease 24–6
isolated LV non-compaction 34
ivabradine 107–8
jugular venous pressure 70–1, 73
left ventricle assist device 126–8
left ventricular dysfunction 7–10, 24–6
left ventricular hypertrophy 19, 27
lifestyle, healthy 83–7
lisinopril 98
liver disease 63–4
loop diuretics 94–6
lung function tests 59
management of HF 78–91
mechanical pumps, LV assistance 126–8
mechlorethamine 46
medication
HF precipitated by 52
withdrawal 142
melphalan 38
metabolic cardiomyopathies 45–6
milrinone 109
mitomycin 46
mitral valve regurgitation 29, 117
mitral valve stenosis 28–30
MOGE(S) nosology system 31
mood disorder see depression
implantable devices 115–17, 119–20
multidisciplinary care 78–9
myocardial fibrosis, resynchronization 117–25
myocardial infarction (MI) 50, 90
myocardial ischemia 50
myocardial remodelling 9–10, 19
natriuretic peptide (NP) system 18–19, 59, 74, 75
nausea and vomiting 140
neprilysin, inhibition 19, 94, 106–7
neurohormones 17–19
nitrates 109
non-ischemic cardiomyopathy 25
non-pharmacological management 115–32
nutrition, self-care 86
NYHA classification 20–1
obesity, cardiomyopathy and 45, 46
obstructive sleep apnea (OSA) 59–61, 87–8
omega-3 polyunsaturated fatty acids 108
pacemakers, cardiac resynchronization 117–25
pain, management 140
palliative care 137–42
pathophysiology of HF 17–20
patiromer 145
peripartum cardiomyopathy 43–4
peripheral edema 30, 44, 97, 141
pharmacological treatment 93–113
first line 95–106
second line 106–13
phrenic nerve stimulation 144–5
potassium-binding resins 145
potassium-sparing diuretics 95, 96
predisposing conditions for HF 12–15
prosthetic valves, mismatch 30
pulmonary disease 58–61
pulmonary valve regurgitation 30
pulmonary valve stenosis 30
reductive LV surgery 126
Remedē System 144–5
renal dysfunction 20, 51, 61–2, 112
digoxin and 108
renal failure
anemia 56
in cardimyopathies 38
end-stage 104
renin-angiotensin-aldosterone system (RAAS) 17–18, 56, 61
blockade 97
restrictive cardiomyopathies 36–41
risk factors for HF 12–15
rivaroxaban 109
sacubitril/valsartan 106–7
sarcoid, cardiac 38–40
selective serotonin receptor inhibitors (SSRIs) 65, 88
self-care management 79–87
sertroline 65
sexual activity 87
skeletal muscle, loss 20
sleep-disordered breathing 59–61, 87–8
smoking 86
sodium intake 79–80
SonR device 124
spironolactone 106
stem cell therapy 144
stress-provoked cardiomyopathy 42–3
sympathetic nervous system (SNS) 17, 18
symptoms of HF 68–70
sympton recognition, self-care 81
SynCardia TAH 129–30
tachycardia-induced cardiomyopathy 44–5
tako-tsubo cardiomyopathy 42–3
telemonitoring/telehomecare 79
terminal care 142
total artificial heart (TAH) 129–30
trastuzumab 46
travel, HF and 88–91
tricuspid valve regurgitation 30
tyrosine kinase inhibitors 46
valsartan 99–100
in ARNI 106–7
valvular heart disease 14, 27–30
vasoconstriction, peripheral 20
vasodilators, acute HF 111, 112
venous thromboembolism (VTE) 90
ventricular arrhythmias 73
ventricular dyssynchrony 117–25
vibration, pacemakers and 91
vitamin B12 deficiency 55–6
warfarin 109
weight monitoring 81–2, 95, 97
self-care 86
worsened HF, causes 49–52
X-ray, chest 74